Headache Disorders Market Forecast 2023-2027 By The Business Research Company
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
The Business Research Company’s headache disorders market report forecasts the headache disorders market size to grow to $5.71 Billion by 2027, with a CAGR (compound annual growth rate) of 7%.
Learn More On The Headache Disorders Market Report 2023 – https://www.thebusinessresearchcompany.com/report/headache-disorders-global-market-report
Headache Disorders Market Size Forecast
The global headache disorders market is expected to grow from $4.07 billion in 2022 to $4.36 billion in 2023 at a compound annual growth rate (CAGR) of 7.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global headache disorders market size is expected to reach $5.71 billion in 2027 at a CAGR of 7%.
North America held the largest headache disorders market share.
Key Headache Disorders Market Driver – Increase In The Prevalence Of Migraine
According to Migraine.com, a subsidiary of the US-based Health Union, LLC that provides people living with chronic conditions with the knowledge, connection, and validation they want, around 39 million people in the United States and 1 billion people globally will have migraine by 2021. As a result, the rising occurrence of migraine is boosting the market for headache diseases.
Request for A Sample Of The Global Headache Disorders Market Report:
Key Headache Disorders Market Trend – Product Innovation
To increase their market position, major businesses in the headache disorder market are focusing on introducing innovative products. For example, AbbVie, a US-based pharmaceutical company that researches, develops, and markets both biopharmaceuticals and small molecule medications, introduced QULIPTATM (atonement) in September 2021, a prescription therapy for the preventative treatment of episodic migraine in adults. It is specifically constructed with oral calcitonin gene-related peptide (CGRP) receptor antagonist (giant) in three dose levels of 10 mg, 30 mg, and 60 mg that have been approved by The United States Food and Drug Administration (FDA), a department of health situated in the United States.
Headache Disorders Market Segment
1) By Type: Migraine, Tension-Type Headache, Cluster Headache, Medication-Overuse Headache, Other Types
2) By Treatment: Medication, Heat Therapy, Diet Changes, Acupuncture, Oxygen Therapy
3) By Diagnosis: Complete Blood Count, Skull X-Rays, Sinus X-Rays, CT Scan, Magnetic Resonance Imaging (MRI)
4) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Headache Disorders Market Major Players and Strategies
Major players in the headache disorders market are Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Novartis AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd, Emcure Pharmaceuticals Limited, Endo International plc, WorldMeds LLC, AstraZeneca plc, Bausch & Lomb Incorporated, Nichi-Iko Pharmaceutical Co, Upsher-Smith Laboratories LLC, Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim International GmbH., Gilead Sciences Inc., and Amgen Inc.
Man and Science SA, a Belgian medical device business, paid an undisclosed sum to buy Palion Medical AS in May 2022. The purchase of Palion Medical complements Man and Science’s headache treatment capabilities and strengthens the company’s capacity to deliver a variety of therapy solutions to improve patient care. Palion Medical AS is a clinical-stage medical device startup based in Germany that is developing a precision injection solution for patients who suffer from terrible chronic migraine and cluster headaches.
The Headache Disorders Global Market Report 2023 covers regional data on headache disorders market size, headache disorders market trends and drivers, opportunities, strategies, and headache disorders market competitor analysis. The countries covered in the headache disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Headache disorder is a neurological illness characterised by severe headaches on one side of the head, typically around the eye. Headache diseases place a huge burden on sufferers, resulting in significant personal anguish, poor quality of life, and financial implications.
View More Reports Related To The Headache Disorders Market –
HPV Associated Disorders Global Market Report 2023
Bleeding Disorders Treatment Global Market Report 2023
Generic Musculoskeletal Disorders Drugs Global Market Report 2023
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: